AstraZeneca’s Calquence (acalabrutinib) in combination with bendamustine and rituximab has been recommended for approval in the European Union (EU) for the treatment of adult patients with previously ...
AstraZeneca announced on Monday that it secured a US regulatory approval and a positive EU recommendation for two of its ...
Wojciech Jurczak, MD, PhD, ​​discusses the future of B-cell lymphoma therapy, with a focus on Bruton's tyrosine kinase ...
DelveInsight’s Non-Hodgkin Lymphoma pipeline report depicts a robust space with 200+ Non-Hodgkin Lymphoma companies working ...
London stocks were set to fall at the open on Monday following heavy losses in Asia, with Donald Trump’s tariffs due to kick ...
(Alliance News) - AstraZeneca PLC on Monday detailed progress with two of its drugs as it reported an endorsement in the EU and an approval in the US.
In just over a year since its US Food and Drug Administration (FDA) approval, pirtobrutinib (Jayprica) has become a standard ...
An Enniskillen-based man will this week share his chemotherapy journey in a festival performance to raise funds for cancer ...
This approval augments Biocon Pharma's complex injectables portfolio and reinforces its footprint in the US pharma market.
An Enniskillen-based man will this week share his chemotherapy journey in a festival performance to raise funds for cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback